drugset / Trial / NCT00444743
Phase 2 Study of MM-093 to Treat Patients With Uveitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the tolerability, pharmacokinetics, pharmacodynamics, and biologic activity of MM-093 in patients with moderate to severe uveitis.
Timeline
- Start
- 2007-02
- Primary completion
- 2008-11
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | MM-093 | Protein / enzyme biologic | 60 mg | Subcutaneous |